Genetic cause of ALS and frontotemporal dementia blocked by RNA-binding compound

December 18, 2018, The Scripps Research Institute
Scripps Research Chemistry Professor Matthew Disney, PhD, goes over a formula in his lab. His group at Scripps Research in Jupiter, Florida has made a potential drug that stops ALS, in early studies. Credit: Scripps Research

Since the ice bucket challenge went viral in 2014, raising awareness and funding for ALS research, scientists have learned much about a disease that disconnects muscles from nerves, leading to muscle atrophy and eventual death. Their ultimate goal is to create medications capable of stopping ALS in its tracks.

Writing in the journal Cell Chemical Biology, Scripps Research chemist Matthew Disney, Ph.D., and colleagues describe a new compound that blocks the most common genetic cause of both familial ALS and frontotemporal dementia. Disney's group is assessing its potential to become a drug to treat both these diseases.

"Hopefully, this will be an accelerant not only for us but for all people in the field working toward a treatment for ALS," Disney says.

The compound works differently than most drugs on the market. Rather than binding with the toxic protein behind the disease, it binds with what's involved in making the protein, a specific form of RNA folded over like a hairpin. Since RNA molecules manage the expression of genes, intervening at the RNA level goes right to the apparent cause of that form of the disease, Disney says.

"There are zero therapies that address the root cause of this disease," Disney says. "Zero. Our goal is not to target the symptoms, it is to target the root cause, which is that RNA."

ALS, short for amyotrophic lateral sclerosis, is also known as Lou Gehrig's disease in honor of the late baseball legend. An estimated 20,000 people in the United States currently live with the neurodegenerative disorder, including former professional football player Tim Green, who recently announced his illness on 60 Minutes.

There are likely multiple causes of ALS. For an estimated 1 in 10 people with ALS, it runs in the family. Around a third of them appear to have inherited the type of DNA damage that Disney's compound targets.

The damaged DNA lies in a non-coding section of the 9th chromosome. There, a stutter-like repeat of letters GGGGCC prompt the cell's protein building machinery to start production of a toxic substance, C9RAN. Disney credits his collaborator, Leonard Petrucelli of the Mayo Clinic in Jacksonville, FL, with co-discovery of the cause. That toxic substance appears to disrupt the nerve cell's normal metabolism, leading to its death, Disney says.

It is the death of the nerve connectors between muscles and the brain that leads to ALS symptoms of muscle atrophy, weakness, difficulty swallowing and breathing. In , the appears to be a cause of neuron death in parts of the brain that control behavior and personality, the frontal and temporal lobes. Disney's compound, a small molecule he designed, is simply referred to as "4," in the paper. It interferes with production of the toxic C9RAN protein, he says.

One important finding of the paper is that the form of the RNA being targeted by many research groups at present may not actually be the one driving neuron death, Disney says.

"There are two different shapes of the protein. The data supports that the shape people have not been looking at is actually the toxic one," he says.

Many questions must be answered before it's clear that the compound "4" could serve as a drug. The research is ongoing, Disney adds.

"We have a long and winding road to make this into a drug. You have to not only show that a molecule works, but that it is safe," he says. "Now that we have a target and we know how to bind it, this should accelerate making compounds that could become drugs in a much more streamlined way."

Explore further: EU approves Disney's deal to buy Fox entertainment assets

More information: Zi-Fu Wang et al, The Hairpin Form of r(G4C2)exp in c9ALS/FTD Is Repeat-Associated Non-ATG Translated and a Target for Bioactive Small Molecules, Cell Chemical Biology (2018). DOI: 10.1016/j.chembiol.2018.10.018

Related Stories

"Disney+" service a year away from streaming shows

November 9, 2018

The Walt Disney Company will launch a "Disney+" streaming service in the United States late next year, boosting it with live-action shows spun from hit "Star Wars" and Marvel hero films.

Scientists create novel RNA repair technology

January 18, 2012

Scientists from the Florida campus of The Scripps Research Institute have identified a compound that can help repair a specific type of defect in RNA, a type of genetic material. The methods in the new study could accelerate ...

Researchers develop strategy to combat genetic ALS, FTD

August 14, 2014

A team of researchers at Mayo Clinic and The Scripps Research Institute in Florida have developed a new therapeutic strategy to combat the most common genetic risk factor for the neurodegenerative disorders amyotrophic lateral ...

Recommended for you

3-D culturing hepatocytes on a liver-on-a-chip device

January 17, 2019

Liver-on-a-chip cell culture devices are attractive biomimetic models in drug discovery, toxicology and tissue engineering research. To maintain specific liver cell functions on a chip in the lab, adequate cell types and ...

This computer program makes pharma patents airtight

January 17, 2019

Routes to making life-saving medications and other pharmaceutical compounds are among the most carefully protected trade secrets in global industry. Building on recent work programming computers to identify synthetic pathways ...

Cultivating 4-D tissues—the self-curving cornea

January 17, 2019

Scientists at Newcastle University have developed a biological system which lets cells form a desired shape by moulding their surrounding material—in the first instance creating a self-curving cornea.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.